Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 441Magnetic Resonance Spectroscopy 340pembrolizumab 286Biopsy 242Carboplatin 228Cisplatin 193Cyclophosphamide 177Paclitaxel 160Nivolumab 152Gemcitabine 147Bevacizumab 123Radiotherapy 120Dexamethasone 110Pemetrexed 101fludarabine 95Fluorouracil 95atezolizumab 90Radiation 90venetoclax 89Docetaxel 88Doxorubicin 86Oxaliplatin 85durvalumab 84Rituximab 83Leucovorin 81Capecitabine 75Prednisone 72Lenalidomide 69X-Rays 67Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cytochrome P-450 CYP2B6 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡